Fig. 4.
Effect of Lym-2 administration on the survival of SCID mice bearing RL lymphoma cells. SCID mice received RL human B-cell lymphomas as described in Materials and Methods. Seven days after IP tumor inoculation of 5 × 106 cells, the mice were injected with Lym-2 (▿) (2 μg), or mouse IgG1 (○) (2 μg) IP every other day for 20 days for a total of 10 injections. The mice were then monitored for tumor growth and survival. Moribund mice were euthanized when they showed evidence of extensive tumor burden. Lym-2 treatment significantly (P < .05) improved survival of RL-bearing mice compared with the isotype control.
